← All Neurocrine Biosciences INC filings

Neurocrine Biosciences INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
NBIX
Neurocrine Biosciences INC
10-K: Neurocrine Biosciences Reports Strong 2025 Sales, Pipeline Advances
Neurocrine Biosciences achieved significant revenue growth in 2025 driven by strong INGREZZA sales and the successful launch of CRENESSITY, while advancing a robust pipeline and navigating evolving regulatory landscapes.
NASDAQ
NBIX
Neurocrine Biosciences INC
10-K: Neurocrine Biosciences Reports Strong INGREZZA Sales, Advances Pipeline in 2024
Neurocrine Biosciences' 2024 10-K filing highlights strong INGREZZA sales, the launch of CRENESSITY, and progress across its neuropsychiatry and neurology pipeline.
NASDAQ
NBIX
Neurocrine Biosciences INC
10-K: Neurocrine Biosciences Reports 2023 Financial Results and Provides Business Update
Neurocrine Biosciences reports a strong financial year in 2023, driven by increased sales of INGREZZA and advancements in its clinical pipeline.